FDA approval removes binary pipeline risk and unlocks first commercial revenue. Watch for early prescription uptake and reimbursement decisions (payer coverage reaching ~80% of lives). Next catalysts: IGNYTE-3 interim OS data and RP2 uveal melanoma/HCC/BTC pipeline readouts. The accelerated approval label includes confirmatory trial risk — a negative IGNYTE-3 result could jeopardize continued approval.
Price Chart
Executive Summary
Replimune announced on August 6, 2026 that the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on a PD-1-based regimen. Continued approval is contingent on verification of clinical benefit in the ongoing confirmatory Phase 3 trial IGNYTE-3. This is Replimune's first approved product, validating its RPx platform and opening a ~10,000 addressable-patient market in the U.S.
Key Facts
- FDA granted accelerated approval for TUDRIQEV (RP1) + nivolumab in advanced melanoma after anti-PD-1 progression
- IGNYTE trial (n=91 efficacy-evaluable): ORR 24.2%, median DOR 14.1 months, 86.1% of responders had DOR >6 months
- No grade 4/5 common adverse events; most adverse reactions were grade 1-2 and transient
- Broad label: no prior BRAF requirement, treat superficial/deep/visceral lesions, retreatment allowed
- Confirmatory Phase 3 trial IGNYTE-3 (N~400, PFS/OS) is ongoing
- First revenue expected in next 6 months; TUDRIQEV expected to ship in ~60 days
- Company has 63,000 sq ft U.S. manufacturing facility; cost of treatment in line with comparable advanced melanoma therapies
Financial Impact
Replimune transitions from pre-revenue biotech to commercial stage; initial revenue expected within 6 months. No revenue or EPS figures provided in filing.
Risk Factors
- Accelerated approval is contingent on positive confirmatory Phase 3 IGNYTE-3 data (OS primary endpoint)
- First commercial product — limited experience in sales, manufacturing scale-up, and market access
- Competition from approved therapies in advanced melanoma (Opdualag, TIL, BRAF/MEK, chemo)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-092246 |
| Document: tm2622487d1_8k.htm | 0001104659-26-092246 |
| Document: tm2622487d1_ex99-1.htm | 0001104659-26-092246 |
| Document: 0001104659-26-092246-index-headers.html | 0001104659-26-092246 |
| Document: 0001104659-26-092246-index.html | 0001104659-26-092246 |
| Document: 0001104659-26-092246.txt | 0001104659-26-092246 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $14.71 $13.07 | ▲ +11.15% | ▲ +11.16% | $13.04 (+11.35%) |
Aug 19, 2026 6w ago | Insider Cluster | $14.05 $13.07 | ▼ −6.98% | ▼ −6.98% | $13.04 (−7.19%) |
Aug 14, 2026 7w ago | 8-K | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 14, 2026 7w ago | Press Release | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 10, 2026 7w ago | Press Release | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 8-K | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 424B5 | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 7, 2026 8w ago | 8-K | $12.06 $15.04 | ▲ +24.71% | ▲ +25.11% | $13.04 (+8.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access